Background:Aberrant activation of B cells and autoantibody mediated tissue damage are hallmarks of autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Therefore, novel treatments that prevent autoantibody generation or antibody-mediated end organ tissue damage are of high interest. Bruton’s tyrosine kinase (BTK) transduces signals downstream of the B cell receptor (BCR), toll-like receptors, and Fc receptors in B cells and myeloid cells [1]. Overexpression of BTK in B cells leads to hyperactive BCR signaling, plasma cell generation, autoantibody secretion, and an SLE-like disease in mice [2]. Conversely, reducing BTK expression in B cells can ameliorate disease in Lyn-deficient mice.[3] BTK inhibitors, such as evobrutinib, have entered clinical studies for the treatment of autoimmune diseases.[4]Objectives:Small molecule-induced protein degradation offers a unique approach to target BTK; this approach simultaneously eliminates both BTK kinase activity and BTK-mediated scaffolding interactions in the signalosome. Chimeric Targeting Molecules (CTMs) are small molecules that catalyze ubiquitylation and proteasomal degradation of target proteins and are comprised of a ubiquitin ligase binding element (“harness”), a linker, and a target binding element (“hook”). NX-5948 is a CTM that contains a BTK hook linked to a cereblon (CRBN) harness. We examined the activity of NX-5948 in a collagen-induced arthritis model as part of an assessment of its potential as a drug candidate for autoimmune disease.Methods:Cellular degradation of BTK, Aiolos and Ikaros as well as induction of CD69 and CD86 was determined using flow cytometry. Degradation of BTK in CD-1 mice or cynomolgus monkey was determined using flow cytometry analysis. In a collagen-induced arthritis (CIA) model, mice were vaccinated with type II collagen and treated before the onset of symptoms. Serum cytokine and anti-type II collagen antibody levels were determined using Luminex and ELISA, respectively.Results:In human PBMCs, NX-5948 degrades BTK at sub-nanomolar concentrations and inhibits BCR signaling as measured by CD69 and CD86 induction in anti-IgM-stimulated B cells with similar potency. Oral administration of NX-5948 in mice leads to BTK degradation to <10% of baseline levels in circulating and splenic B cells. NX-5948 also promotes potent BTK degradation in cynomolgus monkeys, and it can suppress BTK levels to <10% of baseline levels after a single oral dose as low as 10 mg/kg.Unlike IMiD drugs such as lenalidomide, the CRBN harness of NX-5948 was designed to avoid the degradation of known CRBN neo-substrates Aiolos (IKZF3) and Ikaros (IKZF1). In primary human T cells, NX-5948 induces minimal degradation of Aiolos and Ikaros and does not promote IL-2 secretion suggesting that NX-5948 does not convey IMiD activity associated with agents such as lenalidomide.We examined the activity of NX-5948 in a mouse CIA model compared to that of the BTK inhibitor ibrutinib or dexamethasone as a positive control. In mice treated with NX-5948, symptoms of arthritis were resolved, and a significant reduction in arthritis clinical score was observed. Treatment with NX-5948 resulted in a reduction in anti-type II collagen titer and serum levels of the pro-inflammatory cytokine IL-6. Treatment with NX-5948 yielded superior anti-inflammatory activity relative to ibrutinib and similar activity to dexamethasone. Treatment with NX-5948 was well-tolerated and, unlike dexamethasone, did not promote body weight loss.Conclusion:Degradation of BTK by NX-5948 shows robust activity in a CIA model compared to existing agents tested as controls. These findings provide support for further investigation of NX-5948 in additional models of autoimmune disease to inform plans for clinical development.References:[1]Crofford et al. 2016. Expert Rev Clin Immunol 12: 763–773.[2]Kil et al. 2012. Blood 119: 3744-3756.[3]Whyburn et al. 2003. J Immunol 171: 1850-1858.[4]Haselmayer, et. Al. 2019. J Immunol 202: 2888-2906.Disclosure of Interests:DANIEL ROBBINS Shareholder of: Nurix therapeutics, Employee of: Nurix therapeutics, Mark Noviski Shareholder of: Nurix Therapeutics, Employee of: Nurix Therapeutics, May Tan Shareholder of: Nurix Therapeutics, Employee of: Nurix Therapeutics, Cristiana Guiducci Shareholder of: Nurix Therapeutics, Employee of: Nurix Therapeutics, Timothy Ingallinera Shareholder of: Nurix Therapeutics, Employee of: Nurix Therapeutics, Dane Karr Shareholder of: Nurix Therapeutics, Employee of: Nurix Therapeutics, Aileen Kelly Shareholder of: Nurix Therapeutics, Employee of: Nurix Therapeutics, Zef Konst Shareholder of: Nurix Therapeutics, Employee of: Nurix Therapeutics, Austin Tenn-McClellan Shareholder of: Nurix Therapeutics, Employee of: Nurix Therapeutics, Jenny McKinnell Shareholder of: Nurix Therapeutics, Employee of: Nurix Therapeutics, Luz Perez Employee of: Nurix Therapeutics, Gwenn Hansen Shareholder of: Nurix Therapeutics, Employee of: Nurix Therapeutics, Ryan Rountree Shareholder of: Nurix Therapeutics, Employee of: Nurix Therapeutics
Auricular chondritis in rats. An experimental model of relapsing polychondritis induced with type II collagen.